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From summary and commentary
US primary care practices which prescribe
buprenorphine to opioid-dependent patients
generally offer only limited counselling, raising the
issue of whether further psychosocial support
would improve outcomes.
At a US practice, the randomised study trialled
supplementing medical care w ith cognitive-
behavioural therapy.
There was no statistically significant indication
that adding these sessions further reduced opioid
or cocaine use or improved the treatment
completion rate or other outcomes.
Some patients in opiate substitute prescribing
programmes have however benefited from extra
counselling or therapy. Patients w ith psychiatric
problems may particularly benefit.
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Provide psychosocial therapy as well as buprenorphine, or extend treatment to more opioid-dependent patients by not
requiring therapy? Across the relatively uncomplicated patients studied at a primary care clinic, this US study found
no benefit from cognitive-behavioural therapy, but some patients may need this kind of support to make the most of
buprenorphine or methadone treatment.
SUMMARY [In the USA the advent of the buprenorphine/naloxone combination medication (marketed as Suboxone) has
helped promote primary-care based treatment of addiction to opioids like heroin. Meant to be dissolved under the
tongue, buprenorphine is safer in overdose than methadone but also an effective substitute to illegal opiate-type drugs,
and the combination with naloxone helps deter misuse by injection.] Generally primary care practices offer only limited
counselling along with buprenorphine, raising the issue of whether more psychosocial support would improve outcomes.
In particular, the featured trial conducted at a US hospital’s primary care centre investigated whether adding cognitive-
behavioural therapy to medical care of patients prescribed Suboxone would further reduce illegal substance use and
improve retention in treatment.
Over three years the study recruited 141 opioid-dependent
patients seeking treatment at the centre. All were offered 26
weeks (including a two-week induction period) of treatment
involving maintenance doses of Suboxone plus a manualised
programme of medical care by their doctor. Doses were raised to
at least 16mg buprenorphine daily and more if required, averaging
nearly 18mg. Three of the weekly doses were administered under
supervision by clinic nurses and the remainder provided to
patients to take at home. The 15–20-minute consultations with
the doctor were weekly for the first two weeks then fortnightly
for the next four weeks and monthly thereafter. During these the
doctor reviewed the patient’s recent drug use, and reviewed and
supported the patient’s efforts to reduce drug use or remain
abstinent. Drug use data available to the doctor, including the
results of weekly urine tests, were also used to assess
outcomes. Patients were excluded from the trial if also
dependent on alcohol, benzodiazepine or cocaine or suffering
serious and/or dangerous forms of mental disturbance.
The 141 patients who started the trial were those left after 177
otherwise eligible patients failed to progress to the randomisation
phase of the trial, mostly because they lost contact or chose
other treatments. Typically they were white men in their early
thirties and not in full-time employment. About a third were injecting. They rarely used either alcohol or cocaine. Most
had previously been treated for their substance use problems.
Of the 141 patients, 70 were allocated at random to also be offered cognitive-behavioural therapy provided by
clinicians trained to be competent in delivering the manual-guided programme, and who underwent weekly supervision
based on session recordings. The 50-minute sessions were scheduled weekly over the first 12 weeks of treatment, and
focused on coping with craving for drugs and enhancing the patient’s decision-making and their ability to resist drug
use.
Main findings
Only a minority of patients completed the study and barely more than 50% of the cognitive-behavioural sessions were
attended. Both may have made it difficult to establish positive impacts. In the event, regardless of the assumptions
made about missing data, there was no statistically significant indication that adding these sessions to medical care
further reduced opioid or cocaine use or improved the treatment completion rate or other outcomes; more below.
Only 45% of the 71 medical care only patients and 39% of the 70 also offered therapy completed the 24 weeks of
treatment. Due to continuing opioid use despite the buprenorphine dose being increased to 24mg, or due to the
development of marked psychiatric symptoms, 19 therapy patients had been transferred to alternative treatments for
their own protection, and 24 not offered therapy. Most of the other non-completers were removed because they
missed medication visits or appointments with their doctors. Completion and protective transfer rates did not
significantly differ between the two sets of patients. On average just under seven of the 12 possible cognitive-
behavioural therapy sessions were attended.
Given the association between leaving treatment and relapse to illicit opioid use, missing urine tests (about 29% were
missing) and patient follow-up data (24% missing) were treated as if the patient has relapsed. However, the pattern of
results did not differ significantly when other assumptions were made.
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results did not differ significantly when other assumptions were made.
Whether offered cognitive-behavioural therapy or not, by their own accounts patients rapidly and sustainably reduced
non-prescribed opioid use from 5.3 days a week before treatment just 0.8 days during the two-week induction phase
and then 0.6 and 0.4 days in successive 12-week periods. These findings were confirmed by urinalysis results. On no
measure of opioid use or trends in use did the two sets of patients significantly differ. The same was true of cocaine
use.
The authors’ conclusions
Supplementing standard medical management with cognitive-behavioural therapy did not further reduce opioid use or
promote abstinence among primary care patients being maintained on buprenorphine. Though in other circumstances
ancillary psychosocial services have improved outcomes among patients being prescribed opiate substitutes, the
findings of the featured study were consistent with earlier research among primary care buprenorphine patients which
found no benefits from more extended counselling or more frequent visits to the clinic to obtain medication.
These findings suggest that inability to provide formal psychosocial therapies or extended counselling should not be a
barrier to extending buprenorphine-based treatment of opioid dependence in primary care settings. For some patients, a
relatively low level of supportive services, like that provided by primary care physicians for other common medical and
psychiatric conditions such as diabetes and depression, is sufficient to generate abstinence and retention in treatment,
though in this study many had to or chose to leave treatment early.
The study did however exclude patients with other forms of dependence who might have benefited from further
psychosocial therapy. Also, the medical management programme might have been harder to improve on than typical
primary care practice due to its intensity and delivery by physicians experienced in providing buprenorphine-based
treatment.
 COMMENTARY Despite this study’s findings and their congruence with other findings, the evidence does
not enable us to be sure of the effectiveness (and allied to that, the safety) of switching to virtually counselling-free
maintenance programmes on a long-term basis, particularly for more severely disturbed patients. The findings do,
however, call into question the cost-effectiveness of universally providing extended counselling or structured
psychosocial therapy. For many methadone and buprenorphine patients, the impact of entering treatment and being
prescribed an opiate-type drug is powerful enough to make further support in the form of counselling or therapy
redundant. For policymakers, these findings raise the issue of whether in order to gain harm-reduction and recovery
benefits for the greatest number of patients, buprenorphine and methadone treatment should be spread ‘thin and wide’,
or deepened with recovery-oriented interventions for the fewer patients who want and will benefit from these – and to
whom we can afford to offer them.
Were the doctors just too good?
Both the authors and a commentator have highlighted the intensity and possibly too the quality of the medical
management programme as plausibly accounting for why adding cognitive-behavioural therapy did not improve
outcomes. The impact of the weekly therapy may have been overshadowed by these contacts, plus an adequate dose
of buprenorphine increased as needed and interacting with clinic nurses three times a week.
Conceivably too, the cognitive-behavioural therapy did help, but in ways not reported, such as mental wellbeing, crime-
prevention, health, infection risk, and longer-lasting remission of dependence after prescribing terminated. However,
from another account of the study’s findings it seems self-reported crime was not further reduced by therapy and nor
did these patients experience improved health relative to patients not offered therapy. It is also possible that other
forms of support or therapy may have been more effective.
Whether for the patients in the featured study, any substantial dose either of therapy or medical contact was needed
is called into question by the rapidity of their improvement. Within the first two weeks of treatment, opioid use had
plummeted to on average under a day a week – a typical reaction to the advent of substitute prescribing, which left
little room for further improvement. In turn this is likely to have been a testament to the motivation of patients
prepared to join the study, which most prospective participants had refused. Notably, this rapid reduction in opioid use
was seen at a time when all the patients were still in treatment. Exclusion of patients with complicating conditions may
have meant that those who joined the study were quickly able to take advantage of the opportunity it provided.
However, this does not seem to have been a particularly promising caseload. At least two-thirds had tried prior
treatments and presumably not responded well or sustainably, and three-quarters were without full-time employment.
Their attendance records and the need for many to be removed from the study also suggest a set of patients not
particularly easy to treat.
Related studies testify to the power of substitute prescribing
Allied with the motivation of patients, the results testify to the power of providing adequate doses of substitute opiate-
type drugs, enabling patients to experience the opiate effects they have come to feel they need without having to
engage in illegal use. Partnered with regular, well structured and expert medical care, substitute prescribing is in itself
an intervention hard to better. Other related studies among similar patients generally support this conclusion.
A prior study of primary care buprenorphine patients from the same research stable had found that nearly doubling the
amount of time patients spent being counselled did not further reduce substance use or extend retention in treatment,
leading to the same conclusion as the featured study – that on average, only standard medical care was needed to
extract whatever benefits there were going to be from the treatment. As in the featured study, in this study too,
during the two-week induction phase opiate use had already plummeted to almost the level it would remain during the
next 24 weeks of the study. Accounting for the findings, the lead author explained that “the medication, in and of
itself, is so effective, so you would really need to have a large magnitude of difference in services to demonstrate any
benefit over what the medication is able to provide”.
An earlier pilot study from the same author had suggested the contrary – that adding drug counselling to medical care
did improve outcomes among buprenorphine patients – but numbers were so small that differences were not statistically
significant, suggesting this an anamolous finding. Later a study similar to the featured study tested the impact of
adding cognitive-behavioural therapy to buprenorphine maintenance, but allocated patients to therapy dependent on
the availability of the therapist rather than at random. Therapy patients were also required to attend the clinic three
times a week to take their medication, while non-therapy patients were given their drugs weekly to take at home. Even
at the low daily doses in this study – averaging 12–13mg a day – no statistically significant advantage was gained by
adding therapy and requiring more frequent clinic attendance.
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adding therapy and requiring more frequent clinic attendance.
Though the featured report discounted this comparison, its findings were in line with a synthesis of findings from trials
of supplementing opiate substitute prescribing with psychosocial therapies, most of which involved methadone patients.
Overall and in respect of the type of therapy tested in the featured study, no statistically significant advantage was
gained for therapy patients in reducing illegal opiate use, extending retention, or improved psychological health.
Some may benefit even if on average no differences
An Effectiveness Bank hot topic has addressed the issue of whether extra counselling and therapy augment the
benefits of substitute prescribing programmes. It notes that UK and US guidelines insist that substitute prescribing
without counselling or therapy is substandard treatment, but that the evidence supporting this position is thin.
However, this evidence normally relates to averages across a caseload, not whether individuals within those caseloads
might suffer from a blanket denial of psychosocial support.
Even across a caseload, some studies have found substantial benefits from extra psychosocial inputs, of which the
most convincing was a US study whose patients were typically black single men with extensive criminal histories and
experience of serious psychiatric disorders. Psychiatric severity may have been the key in this study, and certainly
seemed the key in a study at a methadone programme in Philadelphia which recruited the full range of patients seen at
the clinic and randomly allocated some to weekly sessions with professional psychotherapists. Benefits were most
clear-cut for the patients with the most severe psychiatric problems, who consistently recorded greater improvements
when allocated to professional psychotherapy, including a further reduction in days of opiate use. Without
psychotherapy, among these patients opiate use remained virtually unchanged.
Patients dependent on cocaine as well as opioids were excluded from the featured study and from similar primary-care
based buprenorphine maintenance studies, but were the focus of a US trial of offering methadone maintenance patients
group cognitive-behavioural therapy. Compared to methadone treatment alone, the therapy substantially reduced
cocaine use. Once both programmes had ended, it was also more effective than providing vouchers with a monetary
value in response to cocaine-free urine tests.
This draft entry is currently subject to consultation and correction by the study authors and other experts.
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